| Gene symbol | C5 | Synonyms | C5D, C5a, C5b, CPAMD4, ECLZB | Type of gene | protein-coding |
| Chromosome | 9 | Map location | 9q33.2 | dbXrefs | |
| Description | complement C5 | ||||
| GTO ID | GTC3176 |
| Trial ID | NCT05536297 |
| Disease | Macular Degeneration | Geographic Atrophy |
| Altered gene | C5 |
| Therapeutic/Target gene | Target gene |
| Therapy | Aptamer |
| Treatment | Avacincaptad pegol|Zimura;ARC1905 |
| Phase | Phase3 |
| Recruitment status | Active, Not Recruiting |
| Title | An Open-label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients With Geographic Atrophy Who Previously Completed Phase 3 Study ISEE2008 (GATHER2) |
| Year | 2022 |
| Country | Argentina|Canada|Colombia|Croatia|Czechia|France|Germany|Hungary|Israel|Italy|Latvia|Spain|United States |
| Company sponsor | IVERIC bio, Inc. |
| Other ID(s) | ISEE2009 |
| Cohort 1 | |||||||||
|
|||||||||